Investor Relations
-
Message from the Chairman and CEO
We are working to meet the expectations of our shareholders and investors by enhancing corporate value.
-
Business Results For the Fiscal Year Ended March 31, 2020
IR Information
-
-
Sysmex Launches New Products in the Hemostasis Field: Automated Blood Coagulation Analyzers CN-6500/CN-3500
- Using Chemiluminescence Enzyme Immunoassay to Enhance Testing Workflow Efficiency - (PDF：188KB) -
-
The National Cancer Center, the National Center for Global Health and Medicine, and Sysmex Corporation Evaluate a SARS-CoV-2 Antibody Test with Support from the Japan Health Research Promotion Bureau
- Performance Report on an Antibody Detection Reagent Using Clinical Specimens - (PDF：314KB) -
-
The City of Kobe, Kobe City Medical Center General Hospital, and Sysmex Corporation Working to Launch from Kobe the Clinical Implementation of a New Test for the Novel Coronavirus
- Collaborating with Medical Institutions of the Foundation for Biomedical Research and Innovation at Kobe to Strengthen Measures Allowing Early-Stage Diagnosis and Prediction of Severity - (PDF：171KB) -
-
Sysmex to Launch Novel Coronavirus (SARS-CoV-2) Antibody Lab Assay Service and Antibody Measurement Reagents (for Research)
- Using the HISCL™-5000/HISCL™-800 Fully Automated Immunoassay Systems to Realize SARS-CoV-2 Antibody Detection - (PDF：150KB) -
-
Sysmex Obtains First Marketing Approval in Japan for the Automated Hematology Analyzer XN-31 as a Class III Specially Controlled Medical Device to Diagnose Malaria
- For Use as a Measure against Imported Infectious Diseases in Japan and Accelerating its Introduction to the Asian and African Markets - (PDF：178KB)
